HERAMED LIMITED — Capital/Financing Update 2021

Feb 3, 2021

4 February 2021

==> picture [535 x 49] intentionally omitted <==

ASX ANNOUNCEMENT

Completion of AUD $2.3m Placement

• HeraMED successfully raises AUD $2,332,275 via a placement with an attaching option

• Placement received strong support from existing and new sophisticated and institutional investors

• Proceeds to be used to accelerate the commercial roll out of the HeraCare platform and the HeraBEAT device

HeraMED Limited (ASX:HMD) (“HeraMED” or the “Company”), a medical data and technology company leading the digital transformation of maternity care with its proprietary in-home maternity care platform, is pleased to announce that it has successfully obtained commitments to raise AUD $2,332,275 via a share placement to sophisticated and professional investors.

The placement is by way of the issue of 25,914,167 fully paid ordinary shares at 9.0 cents per share raising a total of AUD $2,332,275 to new and existing sophisticated and professional investors. Investors to receive an attaching option on a 1-for-3 basis, subject to shareholder approval at a General Meeting of Shareholders which is anticipated during March 2021. The shares will be issued as follows:

Using the Company’s Listing Rule 7.1 Capacity	13,116,701
Using the Company’s Listing Rule 7.1A Capacity	12,797,466
Total Shares to be issued	25,914,167

The issue price of the shares under the placement represents a 9.1% discount to the last traded price of 9.9 cents per share and an 18% discount to the 5-day volume weighted average price of 10.98 cents per share.

HeraMED CEO and Cofounder, Mr David Groberman said: “I am delighted by the support from both existing and new investors in this placement. The funds will enable HeraMED to progress our well defined commercialisation strategy and ensure we can capitalise on the growing pipeline of opportunities,” he said.

PAC Partners acted as lead manager to the placement and will receive 6% of the total amount raised under the placement and 1,000,000 unlisted options exercisable at $0.20 with a 12-month expiry (subject to shareholder approval).

This announcement has been authorised by the Board of HeraMED Limited.

-ENDS-

HeraMED Limited Company Secretary Media Enquiries CEO and Co-Founder Jonathan Hart Melissa Hamilton David Groberman T: +61 2 8379 2961 Media & Capital Partners M: +972 52 6991188 E: Jonathan@hera-med.com M: +61 4 1775 0274 E: David@hera-med.com E: Melissa.hamilton@mcpartners.com.au

HeraMED Limited ACN 626 295 314 T: +61 2 8379 2961 | A: Suite 3, Level 10, 23-25 Hunter Street SYDNEY NSW 2000

Page 1

==> picture [535 x 49] intentionally omitted <==

About HeraMED Limited (ASX:HMD):

HeraMED is an innovative medical date and technology company leading the digital transformation of maternity care by revolutionising the prenatal and postpartum experience with its hybrid maternity care platform. HeraMED offers a proprietary platform that utilises hardware and software to reshape the Doctor/Patient relationship using its clinically validated in-home foetal and maternal heart rate monitor, HeraBEAT, cloud computing, artificial intelligence, big data, and a digital social networking dashboard.

HeraMED Limited ACN 626 295 314 T: +61 2 8379 2961 | A: Suite 3, Level 10, 23-25 Hunter Street SYDNEY NSW 2000

Page 2